Genomics represents probably the most essential pillar within the ‘OMX-space and is the biggest subsector within the US and Europe (EUR 13.3bn vs. EUR 1.8bn). The second and third...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 06/2022”. The Monitor is a month-to-month printed overview of enterprise...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 06/2022”. The Monitor is a month-to-month revealed overview of enterprise...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Valuation Monitor – Q2 2022”. The FCF Valuation Monitor is a complete valuation evaluation for the...
A latest FCF Life Sciences evaluation confirmed a major decline in funding volumes for European life sciences markets within the first half of 2022 in comparison with 2021. This...
A latest FCF Life Sciences evaluation confirmed a major decline in funding volumes for European life sciences markets within the first half of 2022 in comparison with 2021. This...
Enterprise capital deal volumes within the European life sciences sector reached a record-breaking stage in 2021. Nonetheless, financing volumes decreased considerably by 29% within the first 4 months of...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 04/2022”. The Monitor is a month-to-month printed overview of enterprise...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 05/2022”. The Monitor is a month-to-month printed overview of enterprise...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 05/2022”. The Monitor is a month-to-month printed overview of enterprise...